Kiromic BioPharma Welcomes Two New Directors to its Board
Clinical and Regulatory Affairs Expert Pamela Misajon Brings Drug-Development Expertise Finance and Technology Executive Michael…
Clinical and Regulatory Affairs Expert Pamela Misajon Brings Drug-Development Expertise Finance and Technology Executive Michael…
SAN JUAN, Puerto Rico–(BUSINESS WIRE)–First BanCorp. (the “Corporation”) (NYSE: FBP), the bank holding company for…
LEXINGTON, Mass., July 24, 2023 (GLOBE NEWSWIRE) — GreenLight Biosciences Holdings, PBC (NASDAQ: GRNA) (“GreenLight”…
Expands Board with New Highly Accomplished Independent Director Strengthens Balance Sheet and Implements $15 Million…
CAMBRIDGE, Mass., July 24, 2023 (GLOBE NEWSWIRE) — Sibble & Associates, a leading provider of…
Tuesday, August 8, 2023 at 8:00 a.m. ET Paris, France–(Newsfile Corp. – July 24, 2023)…
Ameresco’s Solar-plus-storage Project with Holy Cross Energy/Colorado Mountain College Receives Top Project of the Year…
Management to host investor conference call and webcast at 5:00pm EDT on that day NEW…
OLD GREENWICH, Conn.–(BUSINESS WIRE)–Ellington Financial Inc. (NYSE: EFC) (the “Company”) today disclosed the following estimated…
GLENDALE, California and New York–(BUSINESS WIRE)–Public Storage (NYSE:PSA) (the “Company”) and Blackstone Real Estate Income…
WALTHAM, Mass., July 24, 2023 (GLOBE NEWSWIRE) — Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical…
WALTHAM, Mass., July 24, 2023 (GLOBE NEWSWIRE) — Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical…
Press release The U.S. Food and Drug Administration Gives the Green Light to Molecure’s Flagship…
Press release The U.S. Food and Drug Administration Gives the Green Light to Molecure’s Flagship…
Curia collaborates with Touchlight to expand its mRNA manufacturing offering to enable access to enzymatic…
Curia collaborates with Touchlight to expand its mRNA manufacturing offering to enable access to enzymatic…
Initial topline data from COVALENT-101 trial revealed 2 complete responses (CRs) out of 5 relapsed/refractory…
Initial topline data from COVALENT-101 trial revealed 2 complete responses (CRs) out of 5 relapsed/refractory…
– Live moderated webcast with members of the GRI Bio management team on Thursday, July…
– Live moderated webcast with members of the GRI Bio management team on Thursday, July…